Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGES: Aminoglycosides in early sepsis
2024-519797-39-00Phase 4Authorised
- Sponsor
- Akershus University Hospital
- Start
- Jul 2025
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gentamicin, cloxacillin, ampicillin, benzylpenicillin, piperacillin + tazobactam and 1 more in sepsis (2 arms), sponsored by Akershus University Hospital. Primary endpoints: Death up to 30 days after randomization and Any acute kidney injury up to 30 days after randomization. Planned start Jul 2025; status: authorised.
02
Drugs
gentamicincloxacillinampicillinbenzylpenicillinpiperacillin + tazobactam
03
Conditions
sepsis
Beyond the preview
Go deeper on 2024-519797-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519797-39-00.